https://auntresodamid.com/iJugHxINePLH1VY/96561

Breaking news

Eli Lilly’s Zepbound and Mounjaro now available in U.S. after shortages, FDA says

Eli Lilly’s Zepbound and Mounjaro now available in U.S. after shortages, FDA says

Business News

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, Dec. 11, 2023. Brendan McDermid | Reuters All doses of Eli Lilly’s highly popular weight loss injection Zepbound and diabetes drug Mounjaro are now available in the U.S., according to an update on the Food and Drug Administration’s drug […]

Eli Lilly’s Zepbound and Mounjaro now available in U.S. after shortages, FDA says Read More »

Biogen beats expectations, hikes outlook as Alzheimer’s drug Leqembi and other new products gain traction

Biogen beats expectations, hikes outlook as Alzheimer’s drug Leqembi and other new products gain traction

Business News

Biogen on Thursday reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance, as the company’s cost cuts showed progress and sales of its breakthrough Alzheimer’s drug, Leqembi, and other new products beat expectations.  Biogen now expects full-year adjusted earnings to come in at $15.75 to $16.25 per share, up from a

Biogen beats expectations, hikes outlook as Alzheimer’s drug Leqembi and other new products gain traction Read More »

Moderna beats estimates but slashes guidance on low EU sales, competitive U.S. vaccine market

Moderna beats estimates but slashes guidance on low EU sales, competitive U.S. vaccine market

Business News

Moderna on Thursday reported second-quarter revenue that beat expectations but slashed its full-year sales guidance, citing lower expected sales in Europe, a “competitive environment” for respiratory vaccines in the U.S. and the potential for deferred international revenue into 2025.  The biotech company now expects 2024 product revenue to come in between $3 billion to $3.5

Moderna beats estimates but slashes guidance on low EU sales, competitive U.S. vaccine market Read More »

Patients on Alzheimer’s drug Leqembi see benefits over three years, Eisai study says

Patients on Alzheimer’s drug Leqembi see benefits over three years, Eisai study says

Business News

The newly FDA approved Alzheimer’s treatment Leqembi is prepared at Abington Neurological Associates in Abington, PA., on Tuesday, November 7, 2023.  Hannah Yoon | The Washington Post | Getty Images The breakthrough Alzheimer’s drug Leqembi slowed disease progression in patients over three years, demonstrating the need for them to stay on the treatment long term,

Patients on Alzheimer’s drug Leqembi see benefits over three years, Eisai study says Read More »

Merck beats earnings expectations, raises sales outlook on strong demand for top drugs like Keytruda

Merck beats earnings expectations, raises sales outlook on strong demand for top drugs like Keytruda

Business News

The exterior view of the entrance to Merck headquarters in Rahway, New Jersey, on Feb. 5, 2024. Spencer Platt | Getty Images Merck on Tuesday reported second-quarter revenue and adjusted earnings that topped Wall Street’s expectations as it saw strong sales from its blockbuster cancer drug Keytruda as well as other treatments in its oncology

Merck beats earnings expectations, raises sales outlook on strong demand for top drugs like Keytruda Read More »

Pfizer beats earnings estimates, hikes full-year outlook as drugmaker cuts costs

Pfizer beats earnings estimates, hikes full-year outlook as drugmaker cuts costs

Business News

Kena Betancur | Corbis News | Getty Images Pfizer on Thursday reported second-quarter revenue and adjusted earnings that blew past expectations and raised its full-year outlook, benefiting from its broad cost-cutting program, better-than-expected sales of its Covid antiviral pill, Paxlovid, and strong non-Covid product sales. The company now expects to book adjusted earnings of $2.45 to $2.65

Pfizer beats earnings estimates, hikes full-year outlook as drugmaker cuts costs Read More »

Older GLP-1 drug from Novo Nordisk may slow Alzheimer’s disease progression by protecting the brain, study says

Older GLP-1 drug from Novo Nordisk may slow Alzheimer’s disease progression by protecting the brain, study says

Business News

A box of the drug Victoza, made by Novo Nordisk Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020. George Frey | Reuters An older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer’s disease by protecting patients’ brains, according to data

Older GLP-1 drug from Novo Nordisk may slow Alzheimer’s disease progression by protecting the brain, study says Read More »

Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs 

Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs 

Business News

The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, on Dec. 27, 2023. Adam Glanzman | Bloomberg | Getty Images Bristol Myers Squibb on Friday reported second-quarter earnings and revenue that topped expectations and raised its full-year guidance as the drugmaker moves to slash costs. The pharmaceutical giant raised its

Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs  Read More »

Viking Therapeutics stock jumps 20% after drugmaker moves weight loss injection to late-stage trial

Viking Therapeutics stock jumps 20% after drugmaker moves weight loss injection to late-stage trial

Business News

Weight loss drug concept. Cr | Istock | Getty Images Shares of Viking Therapeutics jumped more than 20% on Thursday after the biotech company a day earlier announced plans to advance its experimental weight loss injection into a late-stage trial earlier than expected.  It brings the San Diego-based company one step closer to joining the

Viking Therapeutics stock jumps 20% after drugmaker moves weight loss injection to late-stage trial Read More »

Stay Connected

Facebook-f Reddit Pinterest

Subscribe

Subscribe
Subscribe

Don’t miss latest news!

Select list(s):

We don’t spam! Read our [link]privacy policy[/link] for more info.

Scroll to Top